CompletedNot Applicable

DUS on the Prescribing Indications for CPA/EE in 5 European Countries

Germany1,597 participantsStarted 2015-03-06

Plain-language summary

This study was designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers. The primary objective of the study was to characterize the prescribing behaviors for Cyproterone Acetate combined with Ethinyl Estradiol in 5 European countries (Austria, Czech Republic, France, the Netherlands, and Spain), including: * prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol * use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the updated label * concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined hormonal contraceptives * second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the indication acne

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women who are prescribed Cyproterone Acetate combined with Ethinyl Estradiol during the study period * Women who are willing to participate in the drug utilization study Exclusion Criteria: * Women who are not willing to sign the informed consent * Women with a language barrier

What they're measuring

Drug Utilization Pattern of Cyproterone Acetate and Ethinyl Estradiol

Timeframe: within 18 months

Trial details

NCT IDNCT02494297

SponsorCenter for Epidemiology and Health Research, Germany

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-10-31

Results submitted2018-11-07

View on ClinicalTrials.gov More Hirsutism trials